LONDON, July 8 — The shift is quiet but seismic. For three decades, the dominant theory in Alzheimer’s research has been the amyloid cascade hypothesis, first proposed by British neuroscientist John Hardy in 1992. Now, that hypothesis has finally delivered approved therapies.
Hardy, a professor at University College London, co-authored the seminal 1992 paper that argued amyloid beta accumulation triggers the tau pathology and neurodegeneration seen in Alzheimer’s disease. It was a bold claim at the time.
The field had no clear molecular culprit. But Hardy didn’t just theorize. In 1991, he identified mutations in the amyloid precursor protein (APP) gene that cause early-onset familial Alzheimer’s.
That genetic evidence gave the hypothesis its first real anchor. It linked a specific molecular defect directly to the disease.
The Long Road to Drug Approval
For years, critics called the hypothesis a dead end. Drug after drug failed in clinical trials. The field watched billions of dollars vanish on compounds that cleared amyloid but didn’t improve cognition — or worse, caused brain swelling.
Then the data shifted. Anti-amyloid therapies like lecanemab and donanemab have now received regulatory approval.
These drugs are the direct descendants of Hardy’s hypothesis. They target the very amyloid plaques he identified as the initiating event in Alzheimer’s pathology. Hardy’s work guided drug development for three decades.
That is not hyperbole. Every major anti-amyloid program — from the early vaccine trials to the monoclonal antibodies now reaching patients — traces its molecular logic back to that 1992 paper.
Recognition and Impact
In 2016, Hardy received the Breakthrough Prize in Life Sciences, one of the largest scientific awards in the world. The prize recognized his contributions to understanding Alzheimer’s disease at the molecular level. Born in 1954, Hardy has spent his entire career at the intersection of genetics and neurodegeneration.
His work at UCL has trained a generation of researchers who now lead labs across the globe. The trend underneath is this: the amyloid hypothesis is no longer just a theory.
It is a therapeutic platform. The approvals of lecanemab and donanemab represent the first disease-modifying treatments for Alzheimer’s — not just symptom management, but an attempt to alter the underlying biology.
What’s Changing Now
Watch this space. The success of anti-amyloid therapies has opened new questions. If amyloid triggers the cascade, does clearing it later in the disease still help?
How early must treatment begin? And what about the tau pathology that follows amyloid accumulation — can it be reversed once it starts?
Hardy’s hypothesis always predicted that amyloid was the trigger, not the entire disease. The field is now testing whether stopping the trigger early enough can prevent the cascade entirely. The next wave of research will focus on combination therapies — anti-amyloid drugs paired with anti-tau agents, neuroprotective compounds, or anti-inflammatory treatments.
Hardy’s framework provides the roadmap. For patients and families watching this space, the shift is real.
After thirty years of failed trials, the first drugs grounded in Hardy’s hypothesis are now in clinics. The science has moved from the lab bench to the bedside. Consult your doctor for medical advice.
